AIOMEGA® — Precision Airway Medicine
About AIOMEGA®
Innovation · Intellectual Property · Regulatory Responsibility
AIOMEGA® is a precision medical innovation company dedicated to advancing clinician-directed airway care for adult and pediatric patients. Our platform is built on engineering rigor, published clinical evidence, and a disciplined commitment to responsible innovation.
Who We Are
A Precision Medical
Innovation Company
AIOMEGA® develops clinician-directed intraoral medical devices for the treatment of obstructive sleep apnea in adult and pediatric patients. Our flagship platform, AIO Breathe®, is a custom-fabricated, FDA-cleared oral airway device designed to be prescribed and managed by licensed clinicians.
We integrate clinical medicine, engineering biomechanics, and precision digital fabrication into a unified platform — one that supports the professional judgment of the treating clinician at every step of care.
AIOMEGA® was founded by Raghavendra V. Ghuge, MD, DABSM, FAASM, MBA — an adult and pediatric sleep physician with more than 20 years of clinical experience. Dr. Ghuge combines medical training with engineering-driven device development and business expertise from the Duke University Fuqua School of Business.
Clinician-Directed
Evidence-Based
Engineering Precision
Adult + Pediatric
The Founder's Mission
Why AIOMEGA® Exists
AIOMEGA® was founded by Raghavendra V. Ghuge, MD, DABSM, FAASM, MBA — an adult and pediatric sleep physician with more than 20 years of clinical experience. Dr. Ghuge combines medical training with engineering-driven device development and business expertise from the Duke University Fuqua School of Business.
The unmet need he witnessed in clinical practice — patients of all ages without access to a precision, clinician-directed airway solution — became the foundation of AIOMEGA's mission. Innovation begins with an unmet need.
Our Mission
Advancing Clinician-Directed
Airway Care
AIOMEGA® exists to advance the standard of care in airway medicine by equipping licensed clinicians with a structured, evidence-based platform for the prescription and management of AIO Breathe®. Our commitment is to quality, regulatory responsibility, and the ongoing integration of published clinical evidence into the AIOMEGA® platform.
Regulatory Responsibility
AIOMEGA® operates within the regulatory framework governing prescription medical devices. Compliance, labeling accuracy, and clinician supervision are foundational to our platform.
Quality Commitment
Precision digital manufacturing, quality verification against clinician-provided specifications, and continuous platform improvement define our quality culture.
Published Evidence
Clinical research supporting the AIO Breathe® platform has been published in peer-reviewed journals. We do not make claims beyond what the evidence supports.
Protected Innovation
AIOMEGA® protects its medical-device innovation through patents, trademarks, proprietary methods, and controlled know-how — ensuring the integrity of the platform.
Clinician Education
AIOMEGA Breathe Academy™ provides structured, AIOMEGA-led clinician training. Education is controlled, consistent, and delivered directly by AIOMEGA.
Responsible Growth
AIOMEGA® prioritizes sustainable growth grounded in engineering excellence, regulatory awareness, and responsible commercialization.
AIOMEGA Headquarters
Where the Mission
Is Built
AIOMEGA® is headquartered in Tyler, Texas — a center of innovation, research and development, clinician education, and the operational home of the AIOMEGA Breathe Academy™.
From this location, AIOMEGA® coordinates precision device fabrication, clinical support, and the structured education programs that equip licensed clinicians across the country.
Innovation
Engineering-driven medical device development grounded in clinical evidence.
Research & Development
Continuous platform refinement through clinical research and precision engineering.
Education
Home of the AIOMEGA Breathe Academy™ — structured, AIOMEGA-led clinician training.
Operations
Coordinating precision fabrication, clinical support, and quality verification.
Precision Medical Innovation
Engineering Meets
Clinical Medicine
The AIO Breathe® platform represents the integration of clinical sleep medicine, craniofacial biomechanics, and precision digital fabrication. Each device is custom-fabricated to the clinician's prescription, reflecting the unique anatomy and clinical requirements of the individual patient.
AIOMEGA's engineering process incorporates CAD/CAM methodologies, precision SLA printing, and structured quality verification — ensuring that each device is fabricated according to the clinician's prescription and within the mechanical parameters of the design.
The AIOMEGA® platform includes proprietary clinical methodology developed over years of clinical practice and research. This methodology is protected and delivered exclusively through AIOMEGA-controlled channels. It is not publicly disclosed.
Adult Platform
FDA-cleared for patients 18 years and older. Custom-fabricated to clinician prescription.
Pediatric Platform
FDA-cleared for patients ages 6 through 17. Growth-conscious, dentition-adaptive, airway-centric design.
Digital Fabrication
Fully digital workflow from clinician-submitted records through precision SLA printing and quality verification.
Clinician-Directed Care
All prescription, management, and clinical decisions remain under the authority of the treating licensed clinician.
Proprietary Methodology
AIOMEGA® has developed proprietary clinical methodology that is protected and delivered exclusively through controlled AIOMEGA channels.
Intellectual Property
Innovation With Purpose.
Protected for the Future.
AIOMEGA's medical platform is supported by an evolving portfolio of issued patents, distinctive trademarks, and controlled proprietary know-how developed around precision airway medicine.
Patents
15 Issued U.S. Patents
15
Issued U.S. Patents
AIOMEGA's issued patent portfolio covers oral-airway device platforms, dynamic repositioning technologies, controller station systems, and polymeric-nanocomposite innovations in precision airway medicine. Public patent records are searchable through the United States Patent and Trademark Office (USPTO).
U.S. Patent 12,685,665
Maxillary and mandibular devices that prevent disengagement therebetween, controller station, and methods
Oral-airway device and controlled-engagement technology.
U.S. Patent 12,318,325
Maxillary and mandibular devices that prevent disengagement therebetween, controller station, and methods
Oral-airway device and controlled-engagement technology.
U.S. Patent 12,376,987
Dynamic mandibular and lingual repositioning devices, controller station, and methods
Dynamic oral-airway device and controller technologies.
U.S. Patent 12,029,679
Dynamic mandibular and lingual repositioning devices, controller station, and methods of treating and/or diagnosing medical disorders
Dynamic oral-airway and controller technologies.
U.S. Patent 12,478,500
Maxillary devices, controller station, and methods of treating and/or diagnosing medical disorders
Maxillary-device and controller technologies.
U.S. Patent 11,666,477
Lingual repositioning devices, controller station, and methods of treating and/or diagnosing medical disorders
Lingual-repositioning and controller technologies.
U.S. Patent 11,666,478
Maxillary devices, controller station, and methods of treating and/or diagnosing medical disorders
Maxillary-device and controller technologies.
U.S. Patents 11,484,434 + 11,484,435
Dynamic mandibular and lingual repositioning devices, controller station, and methods of treating and/or diagnosing medical disorders
Related issued rights involving dynamic oral-airway and controller technologies.
U.S. Patent 12,636,127
Mandibular or maxillary devices having a polymeric nanocomposite actively controlled for hard palate or mandibular growth
Polymeric-nanocomposite technologies relating to hard-palate or mandibular growth.
Trademarks
AIOMEGA® maintains a portfolio of registered and pending trademarks covering its medical device brands and clinical education platform. Unauthorized use of AIOMEGA® trademarks is prohibited.
AIOMEGA®
Primary medical device brand
AIO Breathe®
FDA-cleared oral airway device platform
CAOM®
Registered trademark
SMART-Rx™
Proprietary prescription framework identifier
AIO-Rx™
Proprietary prescription guidance identifier
AAVOAT™
Proprietary clinical methodology identifier
AIOMEGA Breathe Academy™
Clinician education platform
® denotes registered trademark status. ™ denotes trademark claimed. Trademark status is subject to applicable registration and use requirements. Unauthorized use of any AIOMEGA® trademark is prohibited.
Proprietary Know-How
Patents Protect
Invention.
Trademarks Protect
Identity.
Controlled Know-How Protects
Expertise.
AIOMEGA protects proprietary clinical, engineering, educational, and operational know-how in addition to its issued patents and distinctive brands.
Regulatory + Quality
Regulatory Responsibility
AIOMEGA® operates within the regulatory framework governing prescription medical devices. AIO Breathe® is FDA-cleared and intended to be used under the supervision of a licensed clinician.
FDA Clearance
AIO Breathe® is FDA-cleared for the treatment of mild to moderate obstructive sleep apnea (OSA) and snoring. Clearance covers both the adult platform (18 years and older) and the pediatric platform (ages 6 through 17).
- FDA-cleared prescription medical device
- Adult platform: 18 years and older
- Pediatric platform: ages 6 through 17
- Indicated for mild to moderate OSA and snoring
- Intended for use under licensed clinician supervision
Quality Commitment
AIOMEGA® is committed to quality across every aspect of the AIO Breathe® platform. Our processes are informed by established regulatory principles and quality-system expectations.
- QMSR-aligned quality practices
- ISO 13485-style design controls
- ISO 10993-compliant material selection
- Validated manufacturing workflows
- Device-level traceability
- Structured post-market surveillance
These references describe the concepts that guide our internal processes and are not intended to imply certification or regulatory designation.
Regulatory Note
AIO Breathe® and AIO Breathe® Pediatric Device System (PDS) are prescription-only medical devices. They are intended to be used under the supervision of a licensed clinician. The information on this website is provided for general informational purposes only and does not constitute medical advice. Clinicians and patients should consult applicable regulatory guidance and the device Instructions for Use (IFU) for complete prescribing and safety information.
Published Evidence
Grounded in Peer-Reviewed Research
AIO Breathe® clinical evidence has been published in SLEEP — the official journal of the Sleep Research Society. AIOMEGA® does not make outcome claims beyond what is supported by published evidence.
Scientific Milestones
From Evidence to Platform
AIOMEGA® has presented its clinical research at leading national sleep medicine conferences. Each milestone represents a step in the ongoing scientific program supporting AIO Breathe®.
Milestone 01
Seattle · SLEEP 2025
AIO Breathe® received FDA 510(k) clearance (K233754) on February 23, 2024, for the treatment of obstructive sleep apnea in adult patients. At SLEEP 2025 in Seattle, AIOMEGA® presented its first two peer-reviewed publications, marking the platform's formal entry into the published scientific record.
The adult AIO Breathe® platform was the focus of both presentations, establishing the clinical foundation for the program.
Milestone 02
Chicago · AADSM 2026
In May 2026 in Chicago, AIOMEGA® unveiled the pediatric AIO Breathe® platform following FDA 510(k) clearance (K252525) on November 6, 2025, for the treatment of obstructive sleep apnea in pediatric patients ages 6 through 17.
Two poster presentations were delivered at AADSM 2026, marking the first professional conference introduction of the pediatric platform alongside the established adult program.
Milestone 03
Baltimore · SLEEP-APSS 2026
In June 2026 in Baltimore, AIOMEGA® continued and expanded its scientific program at SLEEP-APSS 2026. Three publications and presentations were delivered — two adult and one pediatric — representing the continued growth of the AIO Breathe® evidence base.
The professional banners introduced in Chicago were carried forward to Baltimore, reflecting the unified adult and pediatric platform.
A Patient Story
Gabriel's Journey
Gabriel was the first pediatric patient to receive the AIO Breathe® device. His story is shared here with the full consent of his family.
Gabriel received the first pediatric AIO Breathe® device in February 2026, at age 12. His was an individual, consented patient journey — not a clinical trial, and not representative of outcomes for all patients.
Following his device dispensing, Gabriel continued his participation in cross-country and soccer. His family has authorized the sharing of his story and photographs as part of AIOMEGA's commitment to transparency about the pediatric platform.
Gabriel's individual experience is not peer-reviewed clinical evidence and does not represent a claim about outcomes for other patients.
Responsible Innovation
Built to Last
AIOMEGA® advances the platform through published evidence, structured clinician education, and disciplined engineering — with a long-term commitment to responsible innovation in precision airway medicine.
Evidence First
Clinical claims are grounded in published peer-reviewed research. AIOMEGA® does not make outcome claims beyond what the evidence supports.
Engineering Integrity
Every device is fabricated to the clinician's prescription through a validated digital workflow. Quality is verified against submitted records.
Regulatory Alignment
AIOMEGA® operates within the regulatory framework governing prescription medical devices, with ongoing attention to labeling accuracy and post-market responsibility.
IP Protection
AIOMEGA® protects its innovations through patents, trademarks, and controlled know-how — ensuring the integrity and exclusivity of the platform.
Controlled Education
Clinician training is delivered exclusively through AIOMEGA-controlled channels. The proprietary curriculum is not publicly disclosed.
Clinician Partnership
AIOMEGA® is built on a partnership with licensed clinicians. Every platform decision is made with the clinician's professional authority in mind.
Leadership
Founded by a Sleep Physician
AIOMEGA® was founded by Raghavendra V. Ghuge, MD, DABSM, FAASM, MBA — an adult and pediatric sleep physician with more than 20 years of clinical experience in sleep medicine.
Dr. Ghuge combines medical training with engineering-driven device development and business expertise from the Duke University Fuqua School of Business. His work spans clinical care, invention, intellectual-property development, and the creation of clinician-directed digital workflows that emphasize safety, clarity, and responsible innovation.
AIOMEGA® is headquartered in Tyler, Texas.
Contact AIOMEGA®
Phone: (903) 787-7533
Fax: (903) 787-8825
Email: info@aiomd.com
Address: 3187 Paluxy Drive, Tyler, Texas 75701
Location: Tyler, Texas
For investor or strategic partnership inquiries, please contact info@aiomd.com. Include your name, organization, contact information, and area of interest.